Second-line platinum-based chemotherapy after enfortumab vedotin plus pembrolizumab in advanced urothelial carcinoma: a systematic review

Materials for a systematic review of second-line platinum-based chemotherapy after first-line enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial carcinoma.

Authors

Publication Details

Journal
Open Science Framework
Published
2026-11-17
DOI
https://doi.org/10.17605/osf.io/8gc7m
Primary Topic
Bladder and Urothelial Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Second-line platinum-based chemotherapy after enfortumab vedotin plus pembrolizumab in advanced urothelial carcinoma: a systematic review

Shugo Yajima
4 links
Open Science Framework
Bladder and Urothelial Cancer Treatments
article

Second-line platinum-based chemotherapy after enfortumab vedotin plus pembrolizumab in advanced urothelial carcinoma: a systematic review

Shugo Yajima
article en

Abstract

Materials for a systematic review of second-line platinum-based chemotherapy after first-line enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial carcinoma.

Open Science Framework
Good health and well-being
Bladder and Urothelial Cancer Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon